Verastem, Inc. VSTM 深 沪
等待开盘 06-25 09:30:00 美东时间
3.85
-0.360
-8.55%
华盛通- 最 高4.3971
- 今 开4.20
- 成交量 297.56万股
- 最 低 3.83
- 昨 收 4.21
- 总市值 3.38亿
- 52周最高 11.245
- 市盈率 静 --
- 换手率 3.39%
- 52周最低 3.55
- 委 比 69.87%
- 总股本 8787.36万
- 历史最高 225.84
- 量 比 1.12
- 振 幅 13.47%
- 历史最低 2.10
- 每 手 1
- 风险率 1.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
今天 11:32
BTIG Reiterates Buy on Verastem, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
06-24 18:02
Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity Observed
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375, an investigational oral KRAS G12D ...
06-24 04:03
Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial (NCT07644559) evaluating VS-7375, an inve...
06-17 04:02
Verastem Obtains U.S. FDA Fast Track Designation For VS-7375; Phase 1 TARGET-D 101 Dose Escalation, Dose Expansion, And Combination Clinical Trial Ongoing With Early Data Updates Expected In The First Half Of 2026 And More Mature Data Expected In The Second Half Of 2026
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has
06-04 04:04
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
BTIG Maintains Buy on Verastem, Lowers Price Target to $18
BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $19 to $18.
05-08 20:10
Verastem Oncology Rolls Out Its Reimagine Recurrent Low-Grade Serous Ovarian Cancer Campaign For AVMAPKI FAKZYNJA CO-PACK
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous
04-30 19:38
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
